ScienceDaily
•77% Informative
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
The immunotherapy created an immune response against cancer and was well tolerated, with adverse events including fatigue, injection site pain and fever.
The mRNA immunotherapy is targeted for patients with lung cancer, melanoma and other solid tumours.
VR Score
86
Informative language
92
Neutral language
28
Article tone
formal
Language
English
Language complexity
72
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links